Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3% in the afternoon session after the stock benefited as investors rotated capital out of the volatile technology sector and into defensive names.
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers.
On Dec. 8, 2025, Eli Lilly increased its dividend by 15.33%, from $1.50 to $1.73 per share. The dividend is payable on March 10, 2026 to shareholders of record on Feb. 13, 2026.
The U.S. stock market is currently experiencing a striking divergence in performance, with the venerable Dow Jones Industrial Average and the broad-based S&P 500 Index ascending to unprecedented record highs, while the technology-heavy Nasdaq Composite finds itself struggling in their wake. This "Great Divergence," observed around December 12,
The venerable Dow Jones Industrial Average (DJIA) has once again captured headlines, surging to unprecedented intraday record highs around December 2025. This remarkable ascent, which saw the blue-chip index breach the 48,000 mark in November and reach a new peak of 48,704 on December 11, 2025, continuing its
The financial markets roared to an emphatic close on December 11, 2025, with major indices shattering previous records in a session defined by widespread optimism and robust investor confidence. This monumental surge, fueled by a potent cocktail of stronger-than-expected corporate earnings, encouraging inflation data, and a perceived dovish pivot from
As December 2025 unfolds, global financial markets are characterized by a delicate balance of cautious optimism and persistent uncertainty. A "Santa Claus rally" sentiment prevails, fueled by expectations of central bank easing and a surprisingly resilient, albeit slowing, global economy. While the technology sector continues its role as a primary
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the year-to-date performance figures as of December 11, 2025, still crown growth equities as the overall victors, a closer look reveals
